vs
Side-by-side financial comparison of Inventiva S.A. (IVA) and PALISADE BIO, INC. (PALI). Click either name above to swap in a different company.
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients living with fibrosis, rare diseases, and oncological conditions. It advances a pipeline of targeted product candidates, with key operations across Europe and North America, serving patient populations with high unmet medical needs worldwide.
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm developing novel therapies for gastrointestinal and associated inflammatory disorders. Its lead product candidates address unmet medical needs including post-surgical intestinal complications and chronic digestive conditions, operating primarily in the U.S. healthcare market.
IVA vs PALI — Head-to-Head
Income Statement — Q2 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.1K | $0 |
| Net Profit | $-49.0M | — |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | -961352.9% | — |
| Revenue YoY | — | — |
| Net Profit YoY | — | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $0 | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $0 | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | $5.1K | $0 | ||
| Q1 24 | — | $0 |
| Q4 25 | — | — | ||
| Q3 25 | — | $-2.9M | ||
| Q2 25 | — | $-2.8M | ||
| Q1 25 | — | $-2.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-3.5M | ||
| Q2 24 | $-49.0M | $-4.1M | ||
| Q1 24 | — | $-3.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -961352.9% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.38 | ||
| Q2 25 | — | $-0.58 | ||
| Q1 25 | — | $-0.47 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-2.32 | ||
| Q2 24 | — | $-3.32 | ||
| Q1 24 | — | $-4.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.0M | $133.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-85.4M | $129.4M |
| Total Assets | $42.6M | $134.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $133.4M | ||
| Q3 25 | — | $5.2M | ||
| Q2 25 | — | $5.4M | ||
| Q1 25 | — | $7.2M | ||
| Q4 24 | — | $9.8M | ||
| Q3 24 | — | $8.0M | ||
| Q2 24 | $11.0M | $11.4M | ||
| Q1 24 | — | $11.3M |
| Q4 25 | — | $129.4M | ||
| Q3 25 | — | $3.2M | ||
| Q2 25 | — | $2.6M | ||
| Q1 25 | — | $5.3M | ||
| Q4 24 | — | $7.5M | ||
| Q3 24 | — | $6.6M | ||
| Q2 24 | $-85.4M | $9.9M | ||
| Q1 24 | — | $10.1M |
| Q4 25 | — | $134.3M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | — | $6.7M | ||
| Q1 25 | — | $8.2M | ||
| Q4 24 | — | $10.9M | ||
| Q3 24 | — | $9.3M | ||
| Q2 24 | $42.6M | $12.9M | ||
| Q1 24 | — | $12.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-10.8M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-10.8M | ||
| Q3 25 | — | $-3.6M | ||
| Q2 25 | — | $-1.8M | ||
| Q1 25 | — | $-2.3M | ||
| Q4 24 | — | $-12.2M | ||
| Q3 24 | — | $-3.1M | ||
| Q2 24 | — | $-3.5M | ||
| Q1 24 | — | $-3.2M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
